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Abstract
Background: Extensive DNA sequencing has led to an unprecedented view of the diversity of
individual genomes and their evolution among patients with clear cell renal cell carcinoma (ccRCC).
Objective: To understand subclonal architecture and dynamics of patient-derived two-dimensional
(2D) and three-dimensional (3D) ccRCC models in vitro, in order to determine whether they mirror
ccRCC inter- and intratumor heterogeneity.
Design, setting, and participants: We have established a comprehensive platform of living renal
cancer cell models from ccRCC surgical specimens.
Outcome measurements and statistical analysis: We conﬁrmed the concordance of 2D and 3D
patient-derived cell (PDC) models with the original tumor tissue in terms of histology, biomarker
expression, cancer driver mutations, and copy number alterations. We addressed inter- and intra-
patient heterogeneity by analyzing clonal dynamics during serial passaging.
Results and limitations: In-depth genetic characterization veriﬁed the presence of heterogeneous
cell populations, and revealed a high degree of similarity between subclonal compositions of
monolayer and organoid cell cultures and the corresponding parental ccRCCs. Clonal dynamics
were evident during serial passaging of cells in vitro, suggesting that PDC cultures can offer insights
into evolutionary potential and treatment susceptibility of ccRCC subclones in vivo. Proof-of-concept
drug proﬁling using selected ccRCC-targeted therapy agents highlighted patient-speciﬁc vulnerabil-
ities in PDC models that could not be anticipated by interrogating commercially available cell lines.
Conclusions: We demonstrate that PDC models mirror inter- and intratumor heterogeneity of ccRCC
in vitro. Based on our ﬁndings, we envision that the use of these models will advance our
understanding of the trajectories that cause genetic diversity and their consequences for treatment
on an individual level.
Patient summary: In this study, we developed two- and three-dimensional patient-derived models
from clear cell renal cell carcinoma (ccRCC) as “mini-tumors in a dish.” We show that these cell
models retain important features of the human ccRCCs such as the profound tumor heterogeneity,
thus highlighting their importance for cancer research and precision medicine.
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1. Introduction
Kidney cancers are a heterogeneous group of chemother-
apy-resistant diseases associated with very high mortality
[1]. The most frequent subtype is clear cell renal cell
carcinoma (ccRCC) that is characterized by specific histo-
pathological features and an almost universal loss of chro-
mosome 3p often concurrent with gain of chromosome 5q
[2–4]. This translocation is considered to produce a small
number of tumor-initiating cells early in life, which over
time acquire the necessary additional genetic alterations,
such as inactivation of the remaining chromosome 3p-
encoded VHL tumor suppressor. These alterations eventu-
ally trigger clinically relevant ccRCC most often in the 7th
decade of life [4,5].
Clear cell RCC is characterized by high levels of intra-
and intertumor heterogeneity that arises from clonal
expansion and parallel evolution driven by the initiating
genetic events [4,6–8]. Recently, extensive multiregional
genetic sequencing has suggested that at least seven
distinct evolutionary patterns of ccRCC tumorigenesis
exist that correlate with clinical phenotypes and contrib-
ute to patient outcome [8]. However, profiling of intra-
tumor genetic heterogeneity has not been integrated
into therapeutic decision making and clinical manage-
ment of ccRCC patients to date. Targeted therapies devel-
oped based on the common molecular underpinning of
ccRCCs have improved patient outcomes only moder-
ately [1,9], and it is plausible that marked inter- and
intratumor heterogeneity of ccRCCs has hampered
their benefit. As tumor cell heterogeneity adds a new
level of complexity to the molecular basis of ccRCC,
preclinical models that can mirror this feature in vitro
would be an attractive approach to advance the under-
standing of ccRCC tumor biology and identify new
therapeutic options. However, the most widely used
human-derived in vitro models to date are monoclonal
cell lines that often fail to capture the genetic complexity
of ccRCC [10–13].
We have established a comprehensive platform of well-
characterized living renal cancer cells. These preclinical
cancer models require no xenografting or exogenous gene
transfer, and are therefore closely related to the human
tumor. We provide a thorough phenotypical and molecular
analysis of two- and three-dimensional (2D and 3D)
patient-derived cell (PDC) models, verifying their concor-
dance with the corresponding patient tumors and their
capability of reflecting ccRCC inter- and intrapatient genetic
heterogeneity. Moreover, we explore the feasibility of drug
testing on different PDC models in order to demonstrate
that ccRCC-derived cell cultures constitute a new genera-
tion of in vitro tools that will expand our understanding of
how inter- and intratumor heterogeneity affects patient
outcomes.
2. Patients and methods
A detailed description of the patients and methods is available in the
Supplementary material.
2.1. Ethics statement
All tissue samples were made available by the Tissue Biobank of the
Department of Pathology and Molecular Pathology, University Hospital
of Zurich, Switzerland. The local ethics commission approved this study
(KEK-ZH-Nr. 2011-0072 and KEK-ZH-Nr. 2014-0614), and all patients
gave written consent.
3. Results
3.1. Establishing a living biobank of PDCs from ccRCCs
In order to develop adequate invitro models of ccRCC, we have
extended routine tumor tissue biobanking with a repository
of patient-derived living cells from human tumors (Fig. 1A).
We obtained surplus tissue from patients, who underwent
ccRCC resection, subsequent to a pathological review. Over a
period of 3 yr, we acquired 35 specimens (Supplementary
Table 1). Targeted sequencing of the VHL gene revealed that
80% of tumors from this cohort (28/35) harbored a somatic
mutation of at leastone allele (Supplementary Table 1). In 74%
of the cases (26/35), we successfully established monolayer
PDC cultures and expanded them for at least three passages
(Fig.1B and Supplementary Table 1; patients 1–26). Doubling
times of PDC monolayer cultures were generally variable, and
usually ranged between 5 d and 4 wk. Importantly, the PDC
cultures generated here were not immortalized, and the
growth conditions that we used stimulated proliferation
for a limited amount of time. Often PDCs underwent senes-
cence after five to ten passages. To facilitate biobanking, we
cryopreserved dissociated tumor cells and validated cells
from early passages, which will continue to proliferate upon
thawing.
VHL sequencing in the cell cultures at various passage
numbers demonstrated that 74% of samples (14/20) dis-
played the same VHL mutation as the primary tumor
(Fig. 1B). Within the detection limit of Sanger sequencing
[14], six PDC cultures failed to exhibit the VHL mutation of
the original ccRCCs, indicating that nontumor cells might
have prevailed during in vitro cell growth. In the six remain-
ing ccRCCs with VHL wild-type mutational status (Supple-
mentary Table 1; patients 1, 14, 16, 20, 22, and 26), cyto-
genetic aberrations of chromosome 3 were analyzed and
found to be matching between parental ccRCCs and corre-
sponding cell cultures (Supplementary Fig. 1A and 1B).
Consequently, we could verify that the genotypic alterations
of the primary tumor were matched by 77% (20/26) of cell
cultures.
In addition, we assessed possible reasons for the failure
of culture derivation in the nine ccRCCs from which no PDC
models could be generated (Supplementary Table 1;
patients 27–35). Genetic and protein expression features
were indistinguishable between tumors from which PDC
cultures could be established and those from which it failed
. On the phenotypic and morphological level, we observed
that tumors of low grade and displaying high levels of
necrosis showed an increased likelihood of failing in cell
culture derivation (Supplementary Table 1 and Supplemen-
tary Fig. 2C).
E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 9 ) X X X – X X X2
EUF-759; No. of Pages 11
Please cite this article in press as: Bolck HA, et al. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-
derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma. Eur Urol Focus (2019), https://doi.org/
10.1016/j.euf.2019.06.009
In order to evaluate whether patient-derived renal cell
models reflect important aspects of ccRCC tumor biology
such as the strong tumor heterogeneity, we next sought to
profile six representative patient cases and corresponding
in vitro cell models by analyzing histology, biomarker
expression, copy number variations, drug responses, and
somatic mutations. Importantly, all the six primary ccRCCs
harbored mutations in the VHL gene (Table 1).
3.2. Histological, molecular and functional characterization of
ccRCC in vitro models
Selected patient-derived monolayer cultures displayed typ-
ical epithelial features, but individual cell cultures differed
in their morphology (Fig. 1C and Supplementary Fig. 1C).
PDC cultures recapitulated hallmarks of ccRCC histology
such as enlarged pleomorphic nuclei and conspicuous
eosinophilic nucleoli. Since prominent nucleoli determine
ccRCC tumor grade, we sought to quantify this parameter in
order to provide an unambiguous comparison between the
original tumors and PDC cultures (Supplementary Fig. 1C).
Importantly, we found that nucleoli sizes correlated with
ccRCC tumor grades. Overall, the nucleolar perimeters that
we measured in PDC cultures were in good agreement with
those of the corresponding parental ccRCCs (Supplementary
Fig. 1C). However, slight variation was evident, particularly
for the PDC cultures derived from patients A, B, and C. We
perceive that this variability could be due to different levels
of cellular changes that occurred during sample processing
of formalin-fixed paraffin-embedded (FFPE) cytoblocks. In
support of this hypothesis, we observed higher levels of
hydropic degeneration and membrane rupture in the hema-
toxylin eosin–stained section of these specimens (Fig. 1C).
We also segmented nuclear features and recorded shape
parameters such as area, perimeter, and eccentricity. These
showed good agreement between FFPE specimens of the
original ccRCCs and corresponding cell cultures, indicating
that morphological parameters were largely preserved dur-
ing cell culture (Supplementary Fig. 1C).
Additionally, expression of the most prevalent biomark-
ers generally agreed between PDC cultures and original
ccRCCs. All PDC cultures retained Pax8 and pan-cytokeratin
Fig. 1 – Establishing a living biobank for ccRCC-derived cell models. (A) Diagram depicting the generation of PDC models from ccRCC surgical
specimens. Fresh tumor tissue is processed into dissociated single cells that are subsequently used to establish two- and three-dimensional (2D and
3D) cell models or cryopreserved for later use. In addition, established cell cultures are frequently viably frozen for biobanking purposes. (B) Bar chart
of ccRCC surgical specimens that have been considered for the generation of PDC cultures over 3 yr. Cell culture derivation was not possible if no
viable cells remained following tissue processing or cells did not proliferate sufficiently in culture. Successfully established cell cultures could be
expanded for at least three passages. In these cases, primary ccRCCs and corresponding cell cultures were subjected to VHL mutation profiling, and the
number of PDC cultures retaining the VHL mutation of the original tumor is indicated. VHL-WT tumors and corresponding cell cultures were further
analyzed by FISH of chromosome 3 (refer to Supplementary Fig. 1). Six representative ccRCC-derived cell cultures were comprehensively characterized.
(C) HE images of primary tumors (FFPE) and corresponding FFPE cytoblocks from PDC cultures for histological evaluation (20T objective). Light
microscope images of the same PDC cultures depict morphology during 2D cell growth (10T objective). Scale bar denotes 50 mm. ccRCC = clear cell
renal cell carcinoma; FFPE = formalin-fixed paraffin embedded; FISH = fluorescence in situ hybridization; HE = hematoxylin eosin; PDC = patient-derived
cell; WT = wild type.
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expression, validating their renal epithelial origin. Similarly,
all but one PDC culture showed expression of the classical
ccRCC-specific markers CAIX and CD10 (Fig. 2A and B, and
Supplementary Fig. 3A–E). Interestingly, two commercially
available ccRCC cell lines (Caki1 and 769 P) did not express
either CAIX or CD10 (Supplementary Fig. 3F).
Genome-wide copy number analysis revealed the pres-
ence of the most common CNAs, loss of chromosome 3p
often concurrent with gain of chromosome 5q, in all pri-
mary ccRCCs of this cohort (Fig. 2C and Supplementary Fig.
4) [4]. PDC cultures retained large-scale CNAs throughout
their genomes with the exception of patient E, for whom the
loss of chromosome 3p appeared to be subclonal in the
tumor and was not captured by the PDCs (Supplementary
Fig. 4). Interestingly, the majority of cell cultures showed
cleaner and more distinct CNA signals than original ccRCCs,
probably due to the selection of dominant subclones during
serial passaging. For example, a subpopulation of cells with
chromosome 7 amplification became more pronounced in
the culture derived from patient A, while subpopulations
with chromosome 8 amplification and chromosome 14 dele-
tions were hardly retained during serial passaging of the cell
culture from patient C.
To functionally analyze a subset of PDC cultures and
compare them with commercially available ccRCC cell
lines, we performed drug profiling with sunitinib, ever-
olimus, and cabozantinib, used for first-, second-, and
third-line treatment of ccRCC, respectively [15] (Fig. 2D
and 2 E). Not unexpectedly, PDC cultures and commer-
cially available cell lines displayed distinct drug sensitiv-
ity profiles (Fig. 2E). Strikingly, we observed substantial
differences in the responses of PDC cultures and commer-
cially available cell lines, particularly toward cabozanti-
nib and everolimus. Caki1 and 769 P cells were almost
resistant to cabozantinib, an inhibitor of the VEGF, MET,
and AXL receptors [16]. In contrast, PDC cultures dis-
played distinct sensitivities toward this agent, which
may be reflective of recent findings presenting it as the
most efficacious newly developed tyrosine kinase inhibi-
tor in vivo [17]. The two cell lines were most susceptible to
the mTOR inhibitor everolimus, which was not matched
by the PDC cultures. From our cohort, only patient E
received adjuvant treatment with pazopanib subsequent
to nephrectomy but exhibited tumor progression under
this therapy. Remarkably, cells derived from this tumor
showed only moderate sensitivity to pazopanib in vitro
(Supplementary Fig. 4G).
3.3. Characterization of patient-specific genetic alterations in
ccRCCs and PDC cultures
In order to define the landscape of genetic alterations in the
six ccRCCs and corresponding PDC cultures, next-genera-
tion sequencing of 409 cancer-related genes was performed.
Overall, genotypes were concordant across patient-
matched normal and tumor tissue as well as corresponding
PDC cultures. Indeed, patient-specific DNA samples clus-
tered together, but signatures differed significantly between
patients (Fig. 3A). The total number of nonsynonymousT
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Fig. 2 – Molecular and functional characterization of ccRCC-derived monolayer cultures. (A) Histopathological analysis of FFPE primary tumor, metastasis
of the adrenal gland, and corresponding FFPE cytoblock from the PDC culture derived of the metastasis (20T objective, insets 40T objective). Consecutive
sections were stained with HE or the indicated antibodies by IHC. Scale bars denotes 100 mm. (B) Summary of biomarker expression in original ccRCC
tumors or metastasis and corresponding PDC cultures as illustrated for patients A–F (Fig. 3A, left side). Representative images are shown in Supplementary
Fig. 2. (C) Genome-wide CNAs of parental ccRCCs and matched PDC cultures. CNAs were derived from CytoScan HD array. Y axis depicts estimated copy
numbers after data normalization on the neutral two-copy level. Green color represents copy number gains and deletions of the primary ccRCCs, and red
color represents the corresponding PDC culture. Genomic profiles indicating Log2 ratios of all samples are shown in Supplementary Fig. 3. (D) Simplified
scheme of the AKT/mTOR signaling pathway including targeted drugs used in ccRCC treatment. (E) Dose-response curves for selected drugs from Fig. 2D.
Cryopreserved cells were thawed, seeded into monolayer cultures for recovery, and subjected to drug profiling with increasing concentrations of the
indicated drugs for 6 d. Cell viability of ccRCC patient–derived cell cultures or commercially available cell lines (769 P and Caki1) in the presence of selected
drugs in vitro was assessed. N  3, data are presented as mean  SEM. ccRCC = clear cell renal cell carcinoma; CNA = copy number aberration; FFPE
= formalin-fixed paraffin embedded; HE = hematoxylin eosin; IHC = immunohistochemistry; PDC = patient-derived cell; SEM = standard error of the mean;
VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial growth factor receptor.
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coding variants was generally stable during cell culture
derivation and propagation (Fig. 3B), indicating that genetic
changes due to cell culture techniques were minimal.
Besides the VHL driver mutations, the six original
ccRCCs and corresponding PDC cultures were affected
by nonsynonymous alterations in relevant ccRCC genes,
such as PBRM1, SETD2, and BAP1, as well as by a number of
additional somatic changes. Importantly, mutations were
consistent between primary tumor and the corresponding
cell cultures, and largely specific to individual patients
reflective of interpatient genetic heterogeneity (Fig. 3C).
Allele frequencies often increased during serial passaging
of PDC cultures, suggesting that certain genetic changes
may confer growth advantages in vitro. A subset of muta-
tions with low or moderate frequencies was observed
only in the primary tumor, particularly of patients A
and D, and could not be continuously detected in the
corresponding cell cultures. The loss of tumor-specific
Fig. 3 – Analysis of cancer gene alterations in ccRCCs and corresponding PDC cultures. (A) Heatmap showing concordance between patient tissue and
corresponding ccRCC-derived cell cultures determined based on a subset of loci, for which at least two different genotypes could be observed across all
samples. Concordance scores are indicated by the color scale. (B) Bar graphs showing the total number of nonsynonymous coding variants (mutation
load) per sample detected by next-generation sequencing of 409 cancer-related genes in patient tissue and corresponding ccRCC-derived cell cultures
at the indicated passage numbers. (C) High-confidence, nonsilent somatic variants identified by NGS in DNA extracted from primary tumor (FFPE
tissue—patients A and D, or dissociated primary cells of the original ccRCC—patients B, C, E, and F) and cultured cells at the designated passage
numbers. VAFs are indicated and correspond to the color scale. VAFs marked with an asterisk were identified by manual inspection only as they failed
to be reported during variant calling. ccRCC = clear cell renal cell carcinoma; FFPE = formalin-fixed paraffin embedded; NGS = next-generation
sequencing; PDC = patient-derived cell; VAF = variant allele frequency.
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variants during cell culturing appeared to be lower when
DNA from PDCs was compared with DNA from fresh
primary tumor cells (Fig. 3C; patients B and C). When
DNA obtained from FFPE tumor tissue was used as a
reference (Fig. 3C; patients A and D–F), the number of
mutations that could not be detected in the associated cell
cultures increased, suggesting the presence of sampling
discrepancies or formalin-induced sequencing artifacts
[18]. Accumulation and loss of mutations during serial
passaging resulted in more distinct genomic signatures in
PDC cultures over time, and also suggested that certain
subclones may have prevailed in culture while others
have diminished.
3.4. Clonal dynamics and retention of intratumor heterogeneity
in ccRCC PDC cultures
Given that recent studies have described profound genetic
intratumor heterogeneity in sporadic ccRCC [4,6,8], we
examined whether the subclonal architecture of parental
ccRCCs was mirrored in their PDC cultures. To assess
dynamics of cancer subpopulations, we applied the tumor
phylogeny reconstruction algorithm PhyloWGS to the
sequencing data of ccRCC samples and corresponding
PDC culture passages [19]. Our analysis revealed that all
PDC cultures were composed of genetically diverse subclo-
nal populations of cells (Fig. 4A–F). The large majority of
Fig. 4 – Clonal dynamics over multiple passages during PDC culturing. (A–F) Plots display clonal structure, and dynamics of the original tumors and
subsequent PDC culture passages for patient samples A–F. Mutation clusters and relative prevalence were inferred by PhyloWGS from bulk population-
level targeted sequencing data. Mutation tree reconstruction allowed the assessment of mutational histories and relationships between subclones.
Variants defining a new node are indicated, and a more detailed list can be found in Supplementary Table 3. PDC = patient-derived cell.
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clones observed in the PDC cultures could be traced back to
the matched patient tumor tissue. Based on population
frequencies of mutations that distinguished subclonal
populations, PhyloWGS was used to infer trees depicting
evolutionary relationships among distinct subpopulations
of cells. This analysis revealed that the subclones of each
ccRCC shared a common ancestor harboring a truncal set of
driver mutations. Additional accumulation of genetic var-
iants resulted in branched evolution of subsequent clones,
which contained variants in both coding and noncoding
regions of the genome (Supplementary Table 3). The clonal
composition of PDC cultures was in general relatively stable
with increasing passage numbers. However, we also
observed dynamic behavior in subclonal architectures, for
instance, during in vitro clonal evolution of the PDC culture
of patient B, clones 3 and 4 were lost after passage 5. This
was consistent with the observation that a small number of
somatic coding variants were not retained during PDC
propagation, such as the NOTCH2, TGM7, and NCOA1 var-
iants that defined clones 3 and 4 in patient B (Fig. 4B and
3C). Although these two subclones expanded initially, they
were later replaced by the ancestral clones 1 and 2 that are
characterized by a different set of mutations (Supplemen-
tary Table 3). Frequently, we observed minor subclones of
the original tumor undergoing significant expansion during
in vitro culturing. Interestingly, many of the mutations
contained in dominant subclones included alterations in
known ccRCC drivers such as SETD2, PBRM1, KMT2C, FGFR3,
and MTOR [8]. For instance, an early clone of the tumor of
patient F that contained MTOR and SETD2 mutations (clone
1) expanded to being almost fully clonal by the time the
corresponding PDC culture reached passage 3 (Fig. 4F and
Supplementary Table 3). Changes in the prevalence of dif-
ferent clones were most substantial in patient A for which
the branch originating from clone 3 (Fig. 4A, blue branch)
was stable over time, while the early clone 1 was replaced
by clone 2 that co-occurred with clones 6 and 7 (Fig. 4A).
Although dynamic clonal behavior was observed in a subset
of PDC cultures (patients A, B, and D), our analysis showed
that for other cultures, such as those derived from patients
C, E, and F, the clonal composition was remarkably stable
over time. It is therefore perceivable that differences in
clonal dynamics observed in PDC culture may mirror the
possibility of parallel evolution of subclones that give rise to
different levels of intratumor heterogeneity in vivo [8,20]. In
summary, our data indicate that subclonal architecture was
highly similar between parental ccRCCs and matched PDC
cultures over several passages.
3.5. Generation of next-generation 3D cancer models and
proof-of-principle analysis of drug responses
Owing to the limited capacity to accurately model the
spatial complexity of human tumors and their microenvi-
ronment, monolayer cell cultures are often considered an
oversimplified cell model. Recently developed 3D culture
technologies promise to resemble and recapitulate the in
vivo tissue environment more accurately [21,22]. In order to
explore 3D cell culture models using patient-derived ccRCC
cells, we thawed cryopreserved specimens to generate
tumor organoids and microtissues. Tumor organoids were
established as previously described [23], and could be
generated from cryopreserved dissociated primary and pas-
saged cells. It is important to note that in contrast to
previously published protocols [23,24], ccRCC-derived orga-
noids had to be cultivated in the absence of inhibitors of the
Rho-associated coiled coil containing protein kinase
(ROCK), as these impaired cell proliferation due to the
synthetic lethal relationship with VHL deficiency [25]. Initial
validation of the organoids was achieved by cytology that
ensured the presence of cells with typical features of malig-
nancy such as multiple pleomorphic nuclei and large
nucleoli (Fig. 5A) [24,26]. Cytological assessment as well
as gross morphology of organoids revealed the presence of
different cell populations within one organoid line possibly
representing distinct subclonal entities. Subclonal compo-
sition of the organoid lines was further corroborated by
genomic profiling and analysis of clonality with PhyloWGS.
Importantly, nonsilent somatic coding variants were mostly
consistent between the original ccRCCs and corresponding
organoid cultures, and similarly to monolayer PDC cultures,
patient-specific mutational signatures were maintained in
vitro (Fig. 5B). Pre-existing subclones of the original ccRCCs
were largely present in the corresponding organoid cultures
(Fig. 5C). However, compared with monolayer PDC cultures,
we noted partially different patterns of selection and expan-
sion of branched subclones. Particularly in the organoid line
derived from patient E, we observed a relative increase of
subpopulations originating from clone 7 (right branch),
which contained sets of mutations not present in the cor-
responding monolayer PDC culture (Fig. 4E). This effect was
less striking in the organoids derived from patient A, for
which the subclonal population that resembled and differed
from those detected in the monolayer PDC cultures seemed
to coexist during organoid culture (Fig. 4A). Taken together
this indicated that clonal dynamics at least partly depend on
cell culture conditions, and further studies are required to
interpret the diversity observed between different
techniques.
Likewise, dissociated primary as well as passaged frozen
cells aggregated into microtissues of about 100–200 mm in
diameter within 3 d under the condition that exogenous
fibroblasts (normal human dermal fibroblasts [nHDFs])
were supplied at a ratio of at least 1:20. However, cell
models validation by immunohistochemistry revealed that
important ccRCC biomarkers were not reliably retained as
the prevalence of the stromal component likely presented a
significant problem (Supplementary Fig. 5A). Moreover, the
addition of nHDFs masked tumor cell–specific mutations
and thus impeded genetic analysis of these cell models.
Organoids and microtissues derived from patient A were
used for a proof-of-principle drug response assay to inves-
tigate whether the effects from monolayer cell models
could be replicated (Supplementary Fig. 5B). Owing to their
nonuniform sizes and morphological heterogeneity in
microplate wells, drug screening of the organoid culture
posed substantial technical challenges and resulted in
larger variability between replicates. Microtissues, on the
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contrary, were evenly sized and easily adaptable to multi-
well drug testing. Overall, monolayer cultures, microtissues,
and organoids derived from the same ccRCC displayed
similar drug sensitivities. Three-dimensional models
showed greater responses to everolimus, and particularly
microtissues were more susceptible to the drug effect at
lower concentrations, indicating that the choice of cell
culture model may influence the efficiency of drug discov-
ery. In the present setting, matched normal PDCs were not
obtained and thus no control was available to assess the
toxicity of the targeted agents. Taken together, our results
show that 3D cell culture technologies can be applied to
PDCs from ccRCCs, and this may enable important advances
in drug discovery and fundamental biology.
4. Discussion
Modeling of renal cancer in vitro forms the basis of transla-
tional research, and is crucial to advance the understanding
and treatment options for the disease. Immortalized RCC cell
lines have served as the workhorse for preclinical studies for
decades, but it is increasingly evident that they often fail to
recapitulate the clinical and molecular heterogeneity of
human renal tumors [10–12]. To achieve a more adequate
representation of ccRCC in vitro, we successfully generated
patient-derived 2D and 3D cell models from surgical speci-
mens and confirmed that they retain features of the corre-
sponding patient tumors, such as histology, biomarker
expression, cancer driver, and CNAs. Our comprehensive
genetic and clonality analyses provided insights into the
capability of modeling patient-specific mutational profiles
and subclonal diversity of ccRCCs in different cell culture
systems [4,6,8]. We present evidence that 2D and 3D PDC
culture models capture ccRCC inter- and intratumor hetero-
geneity, and experimentally confirm that different cell cul-
ture techniques influence clonal dynamics in vitro. We per-
ceive that the observed differences in genetic alterations
between tumor and corresponding PDC models could stem
from the selection of subclonal populations occurring invitro,
but could partly also result from heterogeneity of the original
tumor and consequently from sampling discrepancies. The
former scenario is supported by the finding that several
mutations have higher variant allele frequencies subsequent
to sequential passaging of PDCs. It is likely that these confer a
growth advantage in vitro and may therefore be more readily
detected in PDC cultures. Genetic stability of PDC models was
reflected by the almost complete absence of de novo muta-
tions emerging during cell cultivation. Notably, a recent
Fig. 5 – Generation and characterization of ccRCC patient-derived three-dimensional (3D) organoid models. (A) Histopathological analysis of tumor
organoids generated using Matrigel. Cryopreserved cells from patient A (passage 9), patient B, and patient E (dissociated primary cancer cells) were
used for organoid formation. Brightfield images (20T objective) of tumor organoids; scale bar denotes 30 mm. Pap-stained smears (40T objective) of
tumor organoids showing characteristic features of malignancy (magnified in insets: multiple pleomorphic nuclei, large nucleoli). (B) High-confidence,
nonsilent somatic variants identified by NGS in DNA extracted from primary tumor and organoids. VAFs are indicated and correspond to the color
scale. VAFs marked with an asterisk were identified by manual inspection only as they failed to be reported during variant calling. (C) Plots display
clonal structures of 3D PDC organoids relative to the tumor samples of patients A and E. Mutation clusters and dynamics were inferred by PhyloWGS
from bulk population-level targeted sequencing data. Mutation tree reconstruction allowed the assessment of mutational histories and relationships
between subclones. Coding variants defining a new node are shown, and clusters that overlapped between 2D and 3D cell models are color coded
correspondingly (refer to Fig. 4A and 4E). Clonal dynamics during organoid derivation and propagation are indicated by green and red squares,
respectively, which specify whether the prevalence of subclones increases or decreases in the organoid models relative to the original tumor sample.
ccRCC = clear cell renal cell carcinoma; NGS = next-generation sequencing; PDC = patient-derived cell; VAF = variant allele frequency.
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study highlighting the genetic and clonal evolution of ccRCC
suggested at least seven distinct evolutionary subtypes with
different clinical prognoses [8]. It is an interesting possibility
that PDC cultures can represent the evolutionary potential of
ccRCC subsets in vitro, or may even offer insights into aggres-
siveness and treatment susceptibility of the tumors in
vivo. Indeed, the tumor as well as the cell models derived
from patient A seemed to resemble the BAP1-driven evolu-
tionary subtype with a less complex subclonal architecture,
elevated chromosomal aberrations, and rapid dissemination
tothe adrenal gland. The ccRCC of patient D seemed to harbor
the largest clonal complexity. Moreover, we detected a clonal
mutation in PBRM1 concomitant with chromosomal aberra-
tions, particularly of chromosome 9. Together with the
reported absence of metastasis during follow-up of the
patient, this case is likely associated with the PBRM1-CNA
evolutionary subtype [8]. The PDC cultures that we derived
largely retained the characterizing molecular features defin-
ing ccRCC evolutionary subtypes during serial passaging and
consequently represent attractive tools to study the role of
subclones in invasion, metastasis, or therapy resistance.
Interestingly, a complementary proof-of-concept study
recently indicated the impact of spatial tumor heterogeneity
on drug response patterns by establishing PDC cultures from
different tumor regions and highlighting their distinct drug
response profiles [27]. While truncal driver mutations inher-
ited by all cancer cells could be exploited to find common
drug efficacies, PDC models provide the prerequisite to
investigate drug response profiles specific to subsets of
patients. In fact, proof-of-principle drug sensitivity profiling
on multiple PDC models described here revealed variable
response patterns that were not predictable by either the
genetic analysis of the original ccRCCs or the interrogation of
drugeffects in commerciallyavailable RCC cell lines. State-of-
the-art 3D patient-derived models such as organoids and
microtissuesrepresentcomplementarycellculture tools that
can potentially mirror additional biological aspects such as
spatial interactions of the human tumor [28]. Even though
statistically not representative, we showed that for a selected
case, 2D and 3D cell models displayed comparable drug
sensitivities to clinically approved ccRCC therapeutics. Given
that both clonal composition and responses to anticancer
agents are likely influenced by cell culture system and cul-
turing conditions [13,29,30], it will be interesting to investi-
gate how the use of different technologies affect subclonal
dynamics in vitro and whether this is reflective of tumor
evolution in vivo.
5. Conclusions
Although the implications of several of the findings pre-
sented here need further investigation, our data provide the
first confirmation that patient-derived in vitro models not
only capture ccRCC histology and driver genetic alterations,
but also reflect patient inter- and intratumor heterogeneity.
The presented methods and results will further advance the
generation of essential next-generation cell culture avail-
able for cancer research and the rational design of targeted
treatment strategies for ccRCC.
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